Showing results (181-190 of 195) with videos related to
Sort By:
Pageof 20
Nature Medicine|March 14, 2017
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesHelen Davies, Dominik Glodzik, Sandro Morganella, et al.Nature Communications|May 3, 2016
The topography of mutational processes in breast cancer genomesSandro Morganella, Ludmil B Alexandrov, Dominik Glodzik, et al.European Journal of Cancer (Oxford, England : 1990)|December 29, 2020
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancerNicolò Matteo Luca Battisti, Malcolm W R Reed, Esther Herbert, et al.Cancer Research Communications|October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II StudyClinton Yam, Miral Patel, Holly A Hill, et al.Nature|March 23, 2017
Somatic mutations reveal asymmetric cellular dynamics in the early human embryoYoung Seok Ju, Inigo Martincorena, Moritz Gerstung, et al.Nature Communications|May 24, 2018
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockageMarcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, et al.Nature Communications|March 18, 2018
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockageMarcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, et al.Genome Research|January 30, 2019
The circular RNome of primary breast cancerMarcel Smid, Saskia M Wilting, Katharina Uhr, et al.Genome Research|May 13, 2015
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cellsYoung Seok Ju, Jose M C Tubio, William Mifsud, et al.Cancer Cell|November 18, 2022
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, et al.Pageof 20